Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 4CNS 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Neurofibrosarcoma 1Malignant mesenchymal tumor 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Desmoplastic Small Round Cell Tumor 1Dermatofibrosarcoma 1Chondrosarcoma, Extraskeletal Myxoid 1

Interventions

Temozolomide 62Cyclophosphamide 60Radiotherapy 47Doxorubicin 36Filgrastim 26Irinotecan 24fludarabine 23Radiation 23Gemcitabine 23Magnetic Resonance Spectroscopy 20Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × cixutumumab × Sarcoma × Clear all
NCT00720174 2016-05-17

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
Sarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡